Pharmaceutical company Eli Lilly ... it's a once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the ... 2024 forecasts for the drug, but reined them in again ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound ... pharmacies during drug shortages. Tirzepatide, the active ingredient in Lilly's Zepbound and Mounjaro for Type ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Wall Street's three major indexes rose sharply on Monday with the S&P 500 marking its highest level since early March as a U.S.-China ... weight loss in trial Eli Lilly said on Sunday its drug ...

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...